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Summary
Background Reliable estimates of populations aﬀ ected by diseases are necessary to guide eﬃ  cient allocation of public 
health resources. Sickle haemoglobin (HbS) is the most common and clinically signiﬁ cant haemoglobin structural 
variant, but no contemporary estimates exist of the global populations aﬀ ected. Moreover, the precision of available 
national estimates of heterozygous (AS) and homozygous (SS) neonates is unknown. We aimed to provide evidence-
based estimates at various scales, with uncertainty measures.
Methods Using a database of sickle haemoglobin surveys, we created a contemporary global map of HbS allele 
frequency distribution within a Bayesian geostatistical model. The pairing of this map with demographic data enabled 
calculation of global, regional, and national estimates of the annual number of AS and SS neonates. Subnational 
estimates were also calculated in data-rich areas.
Findings Our map shows subnational spatial heterogeneities and high allele frequencies across most of sub-Saharan 
Africa, the Middle East, and India, as well as gene ﬂ ow following migrations to western Europe and the eastern coast 
of the Americas. Accounting for local heterogeneities and demographic factors, we estimated that the global number 
of neonates aﬀ ected by HbS in 2010 included 5 476 000 (IQR 5 291 000−5 679 000) AS neonates and 312 000 
(294 000−330 000) SS neonates. These global estimates are higher than previous conservative estimates. Important 
diﬀ erences predicted at the national level are discussed.
 Interpretation HbS will have an increasing eﬀ ect on public health systems. Our estimates can help countries and the 
international community gauge the need for appropriate diagnoses and genetic counselling to reduce the number of 
neonates aﬀ ected. Similar mapping and modelling methods could be used for other inherited disorders.
Funding The Wellcome Trust.
Introduction
Sickle haemoglobin (HbS) is the most common 
pathological haemoglobin mutation worldwide.1 This 
mutation is a structural variant of normal adult 
haemoglobin (HbA), which is inherited as a Mendelian 
trait. Carriers, or heterozygotes (AS individuals), inherit 
an HbS allele from one parent and an HbA allele from 
the other. These individuals are usually asymptomatic. 
Homozygotes (SS individuals) who have inherited HbS 
alleles from both parents suﬀ er from sickle cell 
anaemia, which often leads to acute and chronic com-
plications.2 Without treatment, which is rarely available 
in low-income high-burden countries, it is assumed that 
most children born with the disease die in their ﬁ rst 
years of life.3
A map showing the global distribution of the HbS 
allele among indigenous populations has been pub-
lished4 and used for geographical conﬁ rmation of the 
malaria hypothesis, which suggests that the gene 
responsible for sickle haemoglobin disorders could 
reach high frequencies because of the resistance con-
ferred against malaria by the heterozygous carrier state.5 
This map does not, however, reﬂ ect the contemporary 
distribution of the populations with the HbS allele. 
Following human diasporas,6 the HbS allele has spread 
from the highly malarious regions (where it was selected 
for the resistance that it confers to malaria) to most other 
regions worldwide.7 In low-income and middle-income 
countries, the epidemiological transition resulting from 
economic development and improve ments in hygiene, 
nutrition, and public health (including malaria control) 
has contributed to signiﬁ cantly reduced infant and child 
mortality.8 As a consequence, patients with HbS who 
would have previously died undiagnosed in their ﬁ rst 
years of life can now survive into adulthood.9 Despite 
substantial decreases in malaria endemicity worldwide10 
and hence reduced selection pressure for the HbS gene, 
population dynamics dictate that it would take many 
generations for HbS to reach allele fre quencies close to 
zero (for example 100 generations for an initial frequency 
of 0·06 and ﬁ tness values of 1·0 and 0 for AS and SS 
individuals, respectively).11 Additionally, the population 
growth rate is still relatively high in many countries with 
high frequencies of HbS so that, without prenatal 
diagnosis and avoidance strategies,12 existing allele 
frequencies will lead to a progressive increase in the 
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absolute number of SS neonates for many gener ations. 
In high-income coun tries, screening programmes are 
now commonly needed to diagnose HbS in mixed 
populations to provide counselling and to prevent 
serious clinical compli cations.13 These factors strongly 
suggest that the number of AS and SS cases and 
associated care costs will substantially increase over the 
coming decades.12,14–16
In this context, reliable estimates of the populations 
aﬀ ected by haemoglobin disorders are desirable to guide 
public-health priority settings. We aimed to develop a 
new cartographic method to provide global, regional, 
national, and subnational (in data-rich areas) estimates 
of AS and SS neonates accompanied by appropriate 
uncertainty measures. Our study generated the following 
products: (1) a contemporary georeferenced database of 
HbS allele frequency surveys, which will be made freely 
accessible online as part of the Malaria Atlas Project’s 
Repository of Open Access Data (ROAD-MAP); (2) a 
Bayesian model-based geostatistical framework17 that 
uses spatial data to predict allele frequencies in 
unsampled areas and pro duces a continuous global map 
of the contemporary distribution of HbS; (3) global, 
regional, national, and subnational annual estimates of 
HbS neonate heterozygotes and homozygotes with areal 
uncertainty predictions,18 based on Hardy-Weinberg 
equilibrium19,20 and on the pairing of the allele frequency 
predictions with demographic data.
Methods
Database and contemporary map of HbS allele frequency
Online bibliographic searches were done to create a 
database of spatially located surveys of HbS allele fre-
quency, supplemented by various unpublished datasets 
(ﬁ gure 1). The temporal distribution and sample size of 
surveys are shown in the appendix pp 4–10. We excluded 
community surveys for which any selection bias (eg, 
ethnicity or health status) in the sampling methodology 
was stated or suspected. Remaining surveys were 
judged to be representative of the local populations and 
retained only if the sample size and the number of AS 
individuals (and SS individuals when given) were 
reported and they could be georeferenced to the district 
level (second administrative level) or below.21 The input 
data for the model were geographic coordinates 
(latitude and long itude in decimal degrees) and the 
number of HbS and non-HbS alleles in the population 
samples. A Bayesian geostatistical model, described in 
detail previously,4 was ﬁ tted to the data and used to 
predict HbS allele frequencies at unsampled locations 
and generate continuous maps at 5×5 km resolution 
(appendix pp 10–15). Diﬀ erences between these maps 
and the ones previously published4 are further 
highlighted in the appendix pp 17. Validation metrics 
were calculated by com paring the observed allele 
frequency for a 10% random hold-out sample (a subset 
of the data removed from the validation analysis, so 
that the observed values can be compared with the 
predicted values) of the dataset with the prediction 
output created from the thinned 90% subset of the data 
(appendix pp 15–17).
Deﬁ ning estimates of neonates aﬀ ected in 2010
We estimated the number of neonates aﬀ ected in 2010 by 
combining our HbS allele frequency predictions with 
high-resolution population distribution data (ﬁ gure 1) 
from the Global Rural Urban Mapping Project (GRUMP).22 
For each country, the crude birth rate for 2010–15 was 
downloaded from the 2010 online revision population 
database of the UN world population prospects23 and 
combined with the population surfaces to estimate the 
total number of neonates expected in 2010 globally within 
each 5×5 km pixel (appendix pp 19–20).
Aggregating per-pixel HbS allele frequency predictions 
to subnational (for national ﬁ rst-level subdivisions [ie, 
province or district, containing at least two datapoints]), 
national, regional, or global scales, while maintaining 
the correct statistical-dependence structure and there-
fore allowing these estimates to be calculated with 
appropriate credible intervals (CIs)18 required a bespoke 
version of the Bayesian framework developed previously.4 
Tracefile (mbg-infer)
Global georeferenced database of HbS data
(1950–2010)
Model input (n=1211)
Bayesian geostatistical model
LongitudeLatitudeNegativePositive
UN birth rate (per country) GRUMP (1 km × 1 km) Per-pixel simulation (mbg-map)
Areal simulation (mbg-areal-predict) Predicted contemporary distribution of HbS 
allele frequency
(at 5 km × 5 km grid locations)
Global Regional National Sub-national
Annual AS and SS estimates of neonates
Input data Output data Model and experimental procedures
Figure 1: Schematic overview of the methods and Bayesian model-based geostatistical analysis
HbS=sickle haemoglobin. Positive=number of HbS alleles in the population sample. Negative=number of non-HbS 
alleles in the population sample. Mbg-infer=model-based geostatistical inference process based on a Markov chain 
Monte Carlo (MCMC) algorithm. GRUMP=Global Rural Urban Mapping Project. Mbg-map=model-based geostatistical 
mapping process. Mbg-areal-predict=model-based geostatistical areal prediction process. AS=HbS heterozygotes. 
SS=HbS homozygotes.
See Online for appendix
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Here we used simulations from the joint posterior of the 
model parameters and HbS allele frequency at the 
observation locations to generate a posterior predictive 
distribution (PPD) for the HbS frequency surface within 
each area of interest (ﬁ gure 2). Assuming Hardy-
Weinberg equilibrium19,20 with two alleles (HbA and 
A
B
C
Presence
Absence
HbS datapoints
0·18
0·15
0·12
0·09
0·06
0·03
0
HbS allele frequency (%)
IQR
0·11
0·10
0·08
0·06
0·04
0·02
0
Figure 2: Datapoint distribution and maps of the mean and uncertainty in the predicted HbS allele frequency
(A) Distribution of the datapoints. Red circles and blue triangles indicate surveys showing presence and absence of HbS, respectively. (B) Mean of the posterior 
predictive distribution. (C) Bayesian model-based geostatistics prediction uncertainty (posterior standard deviations) of the HbS allele frequency.
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HbS), if x is the HbS allele frequency at a given pixel, x² 
and 2x (1–x) represent SS and AS frequencies, respec-
tively. By integrating samples of these quantities from 
their PPDs over the area of interest, weighted by the 
population density and crude birth rate, we produced a 
PPD for the number of neonates aﬀ ected, from which 
various summary estimates (eg, posterior mean or 
median) and CIs (eg, 95%) could be generated (appen-
dix pp 20–22).
WHO regional country groupings used previously7 
might not be the most useful for summarising HbS 
epidemiology, because of the variable clinical severity of 
the multiple HbS haplotypes24 and its link with malaria 
endemicity.25 We therefore present our results both 
within WHO regions and within modiﬁ ed regional 
groupings, called HbS regions. The rationale for using 
modiﬁ ed regions is described in more detail in the 
appendix pp 22–24.
Results
A total of 1211 spatially unique datapoints (ﬁ gure 2) 
from 435 references (web dataset) matched all our 
inclusion criteria. Of these, 51% (619) were located in 
the African continent, 23% (273) in the Asian continent, 
17% (203) in the Americas, 9% (112) in Europe, and 
<1% (four) in Oceania. Absence of HbS in the 
populations tested was recorded for 292 datapoints, of 
which 117 were in Asia, 86 in Africa, 69 in the Americas, 
17 in Europe, and three in Oceania. 9 032 377 individuals 
were included in the selected surveys with overall 
sample sizes ranging from one to 3 212 374 individuals 
(appendix p 5). The mean overall sample size was 7458 
(SD 105 542) individuals.
To our knowledge, the map presented here, illustrated 
by the mean of the PPD (ﬁ gure 2), is the ﬁ rst carto-
graphic representation of the contemporary distribution 
of sickle haemoglobin globally. Although frequencies 
above 20% have been reported in small samples (<100) 
of speciﬁ c ethnic groups, frequencies above 18% are 
unlikely according to the model at the population level. 
The maximum predicted median allele frequency was 
only identiﬁ ed in one small patch in northern Angola. 
Predictions above 15% were commonly identiﬁ ed in 
that area, as well as around the Gabon Estuary 
(Libreville) and in localised areas in southwestern 
Nigeria (Ibadan) and east of Lake Victoria. Predictions 
between 10·0% and 12·5% were found around the 
areas described above, in two patches in the south of 
the DR Congo and in southern Karnataka, India. 
Frequencies between 7·5% and 12·5% were predicted 
in large areas extending from southern Senegal to 
northern Liberia, and from southern Ghana to northern 
Zambia. Smaller areas of similar frequencies were 
predicted in Belize; in Khalkidhiki, Greece; in north-
eastern Côte d’Ivoire, northwestern Egypt, south of 
Lake Chad, in central Sudan, around Lake Victoria and 
the coast of Kenya, Tanzania, and Mozambique, and on 
the east coast of Madagascar; in southern Turkey, 
southwestern Syria and eastern Saudi Arabia; and in 
Karnataka, Chhattisgarh, and Orissa in India. The 
maximum predicted frequency in South America was 
about 5%. Predicted median frequen cies in western 
Europe and localised patches in North America 
(California, Mississippi, or Alabama) did not exceed 
1%. By contrast with the high HbS allele frequencies 
predicted across most of sub-Saharan Africa, large 
areas where HbS is generally absent were identiﬁ ed in 
the south and Horn of Africa, as well as in Morocco 
and Algeria.
The highest uncertainties in predicted allele fre-
quencies were seen in the western area of the DR Congo 
and in northwestern Angola, where predictions ranged 
between 3% and 14%, corresponding to an IQR of 11% 
(ﬁ gure 2). Relatively high uncertainties (IQR ≥7·5%) 
were seen across most of sub-Saharan Africa and in parts 
of Egypt and Libya; in eastern Cuba, Nicaragua and 
Honduras; in eastern Saudi Arabia; and in Karnataka, 
India. The maximum IQRs in North America and South 
America were 5% and 7%, respectively. Uncertainty up to 
7% was also seen in parts of Greece (1–8%), Syria (0–7%, 
1–8%, and 2–9%, in diﬀ erent parts of the country), and 
Lebanon (2–9%).
Comparison of the PPD predicted from the thinned 
dataset with the known values at the locations from the 
hold-out subset revealed a minimal overall bias, with a 
mean error in allele frequency prediction of 0·2%. The 
mean absolute error, which measures the average 
magnitude of allele frequency prediction errors, was 
3·0%. The predicted allele frequencies are therefore only 
slightly overestimated (ie, mean errors were mostly small 
and positive), but predicted HbS allele frequencies could 
be substantially diﬀ erent from the observed values 
(ie, absolute errors up to 12·5% locally), especially in 
areas with a high short-range heterogeneity in the data 
and where the distribution of the dataset was patchy 
(appendix pp 15–17).
Pairing demographic data with our predicted allele 
frequencies, we estimated that, in 2010, 312 302 (IQR 
294 307–329 729) homozygous SS babies and 5 476 407 
(IQR 5 290 779–5 679 288) heterozygous AS babies were 
born globally (table 1); the total number of neonates 
aﬀ ected was 5 788 709 (IQR 5 585 086–6 009 017). At the 
regional scale, 64·4% of the AS neonates were from sub-
Saharan Africa, 22·7% in the Arab-India region, 7·4% in 
Mean (SE)* Median (SE)* IQR (SE)*† Modell and 
Darlison†
HbAS 5 496 253 (27 780) 5 476 407 (30 783) 5 290 779 (25 205) to 5 679 288 (21 244) ··
HbSS 313 945 (2008) 312 302 (1779) 294 307 (1180) to 329 729 (2401) 222 785‡
Population 6 912 202 000 (crude birth rate 0·0189923). *Monte Carlo standard error. †Neonate estimates from Modell 
and Darlison.7 ‡Estimate falling outside our 90% credible interval.
Table 1: Summary of global annual predicted estimates of neonates with the HbS allele
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the Americas, 5·4% in Eurasia, and 0·1% in southeast 
Asia. Among the SS neonates, we estimated that 75·5% 
were born in sub-Saharan Africa (table 2).
We calculated that 50% of the total AS and SS neonates 
were born in only three countries: Nigeria (1 223 330 [IQR 
1 146 733–1 295 851]), India (1 038 579 [918 557–1 186 209]), 
and DR Congo (527 963 [488 571–568 883]). As the 
heterozygotes represented 94% of this total, the ranking 
is the same for the AS neonates, with an estimated 
1 136 909 (IQR 1 070 320–1 200 907) in Nigeria, 996 563 
(883 210–1 135 290) in India, and 489 745 (455 733–524 014) 
in DR Congo. For SS neonates, the estimates for these 
countries were 85 186 (IQR 76 413–94 945) in Nigeria, 
42 016 (35 347–50 919) in India, corresponding to 88% of 
the homozygous cases in Asia (Arab-India and southeast 
Asia), and 38 217 (32 838–44 870) in DR Congo (ﬁ gures 3–5, 
appendix pp 29–38).
Areal estimates calculated at the subnational level for 
data-rich areas showed principal administrative units 
(eg, provinces or districts) in which the predicted number 
of neonates aﬀ ected were the highest (appendix 
pp 39–44). In DR Congo, we estimated that about a third 
of SS births occurred in three provinces each year: 
Equateur (3730 [IQR 2805–5019]), Katanga (5514 
[4175–7350]), and Province Orientale (3711 [2945–4687]). 
In Nigeria, about 20% of the total number of SS neonates 
was predicted in the states of Lagos (8457 [7047–10 143]), 
Oyo (5315 [4520–6272]), and Kaduna (3722 [2956–4624]). 
In India, 25% of the SS neonates were predicted in the 
Karnataka state (9394 [6936–12 890]). Together, Tamil 
Nadu (5221 [3271–8169]) and Maharashtra (4678 
[3511–6644]) repre sented about another 25% of the 
national SS prediction. Complete subnational estimates 
for data-rich areas are shown in the appendix pp 39–44.
Discussion
Sickle cell anaemia has recently been recognised as a 
global public health problem by the UN and WHO.26 
The burden of this disorder and other haemoglobin 
disorders is expected to increase in the coming decades, 
because of reductions in infant mortality in many low-
income countries and increasing migration from high 
to low HbS-frequency areas worldwide.12 A detailed 
assess ment of our current epidemiological knowledge 
and of the magnitude of the problem is needed to 
deﬁ ne ad equate policies for diagnostics, education, and 
treatment to prevent or manage complications asso-
ciated with sickle cell anaemia. We believe that the ﬁ rst 
contemporary global map of the distribution of sickle 
haemoglobin (ﬁ gure 2) and derived global, regional, 
national, and subnational annual estimates with given 
precision of AS and SS neonates presented in our 
report represent substantial contributions towards this 
goal (tables 1, 2; appendix pp 29–44; panel). The best 
way to reliably assess the situation would gen erally be 
through universal national neonate screening.29 How-
ever, such programmes are rare, especially in areas 
with high HbS frequencies (appendix pp 25–26). Using 
existing survey data, combined with bespoke mapping 
and modelling methods, our aim was not only to update 
previous estimates7 but also to take into account the 
striking geographical variation both in the availability 
of survey data, and in the frequency of HbS between 
and within populations, and to assess the reliability of 
our estimates.
Our map shows that high frequencies of HbS (>10%) 
are almost exclusively encountered in sub-Saharan Africa 
(ﬁ gure 2). The areas of highest frequency in Africa seem 
to reﬂ ect the origins of the diﬀ erent African haplotypes 
Population* Crude birth rate HbAS neonates/year HbSS neonates/year
Mean Median (IQR) % Mean Median (IQR) % Modell and 
Darlison†
WHO regions
AFRO 888 817 0·0357 3 607 022 3 610 851 (3 498 595−3 704 303) 64·2 239 547 238 083 (224 003−253 047) 75·4 184 812‡
AMRO 939 833 0·0162 398 279 391 257 (358 199−435 894) 7·6 13 708 13 104 (11 126−15 606) 4·6 4432‡
EMRO 560 803 0·0249 275 365 256 643 (199 839−327 983) 5·7 10 007 8239 (6012−11 951) 3·6 7389
EURO 893 002 0·0123 127 494 121 601 (99 414−147 505) 2·6 3653 3271 (2408−4366) 1·3 376‡
SEARO 1 789 082 0·0200 1 040 033 1 020 489 (900 452−1 154 480) 20·0 44 132 42 597 (35 022−50 750) 15·1 25 768‡
WPRO 1 840 667 0·0128 2292 1150 (477−2374) 0·0 4 9 (2−33) 0·0 9
HbS regions
Americas 939 724 0·0162 389 892 386 430 (349 253−425 791) 7·4 13 309 12 802 (10 869−15 210) 4·6 ··
Arab-India 1 771 305 0·0219 1 168 805 1 147 477 (1 010 443−1 299 147) 22·7 48 951 46 826 (39 147−56 000) 16·9 ··
Eurasia 1 098 104 0·0139 271 474 256 163 (216 499−310 758) 5·4 8784 7493 (5919−10 090) 3·0 ··
Southeast Asia 2 215 004 0·0133 4854 2535 (1324−5171) 0·1 80 21 (7−63) 0·0 ··
Sub-Saharan Africa 888 065 0·0365 3 579 982 3 580 207 (3 473 117−3 684 718) 64·4 237 253 235 681 (220 993−250 568) 75·5 ··
Crude birth rate data obtained from the UN world population prospects.23 Estimates are shown by WHO regions and HbS regions. See appendix for further details. AFRO=Regional Oﬃ  ce for Africa. 
AMRO=Regional Oﬃ  ce for the Americas. EMRO=Regional Oﬃ  ce for the Eastern Mediterranean Countries. EURO=Regional Oﬃ  ce for Europe. SEARO=Regional Oﬃ  ce for South-East Asia. WPRO=Regional Oﬃ  ce for 
the Western Paciﬁ c. *Population data in thousands. †SS neonate estimates from Modell and Darlison.7 ‡Estimate falling outside our 90% credible interval.
Table 2: Summary of regional annual predicted estimates of HbAS and HbSS neonates
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Figure 3: Comparison plots of 
predicted national SS 
neonate estimates with 
Modell and Darlison’s 
estimates for the AFRO and 
AMRO regions
Red dots show our estimates 
(termed MAP) with IQRs 
shown as red lines. Blue dots 
represent Modell and 
Darlison’s estimates.7 
(A) AFRO. (B) AMRO. 
AFRO=Regional Oﬃ  ce for 
Africa. AMRO=Regional Oﬃ  ce 
for the Americas.
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Figure 4: Comparison plots of 
predicted national SS 
neonate estimates with 
Modell and Darlison’s 
estimates for the EMRO and 
EURO regions
Red dots show our estimates 
(termed MAP) with IQRs 
shown as red lines. Blue dots 
represent Modell and 
Darlison’s estimates.7 
(A) EMRO. (B) EURO. 
EMRO=Regional Oﬃ  ce for the 
Eastern Mediterranean 
Countries. EURO=Regional 
Oﬃ  ce for Europe.
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(Senegal, Benin, and Central African Republic or 
Bantu).30 Frequencies of HbS seem highly heterogeneous 
across the Indian subcontinent. HbS is still rare in 
southeast Asian populations. In the Americas, the 
distribution of HbS, which is common in populations 
along the eastern coast of the continents, mirrors the 
distribution of African Americans. Uncertainties were 
highest in areas for which no data were available, such as 
central DR Congo (ﬁ gure 2). Data in those areas would 
be particularly useful to improve our knowledge of the 
distribution of this gene. Our validation process showed 
that our model performed well in view of the amount of 
data available.
Micromapping studies have shown that HbS frequency 
can greatly vary over short distances.31 We present the 
ﬁ rst evidence-based estimates with precision measures, 
accounting for these spatial heterogeneities (where data 
permits) and demographic factors. Our model-based 
predictions showed large diﬀ erences at the national level 
when compared with previous estimates (appendix 
pp 29–33, 45–48).7 Most neonates with HbS are born 
within speciﬁ c regions in Nigeria, DR Congo, and India 
(ﬁ gures 3–5, appendix pp 29–44). Health interventions 
(eg, screening pro gramme, genetic counselling) in those 
regions would, therefore, have the greatest eﬀ ect on total 
numbers of aﬀ ected neonates.
Due to the kinetics of inherited disorders, the current 
and future public health challenges are twofold. First, 
countries with high HbS allele frequencies need to be 
prepared to provide health care for patients with sickle 
cell anaemia. With substantial reductions in mortality of 
children younger than 5 years of age in many low-
income countries,8 SS neonates who would have 
previously died undiagnosed are now more likely to 
survive to adulthood. These countries, therefore, need 
to know the extent of the problem and to plan eﬃ  cient 
and aﬀ ordable treatment policies to reduce the 
morbidity of these patients during their lifetime.9 
Second, although AS individuals are usually asympto-
matic, it is important to educate carriers about their 
status to try to prevent the future birth of homozygous 
children, as well as to avoid psychosocial issues (eg, 
miscon ceptions or stigma tisation).32 Such education 
programmes are needed not only in low-income 
countries but also in high-income countries.
Without a universal neonate screening programme and 
eﬀ ective data aggregation and analysis systems (appendix 
pp 25–26), it is impossible to know with exact precision 
the number of neonates aﬀ ected by HbS (or any other 
inherited disorder) within a given country. Pilot screening 
programmes are under way in several African countries 
and India, which should help update our knowledge of the 
current distribution of HbS and reﬁ ne our estimates in 
many areas. Better accessibility to data in high-income 
countries (eg, USA and UK) would also be valuable.
While the approach presented in our report represents 
a substantial advance in both the methodology and 
underlying evidence base compared with earlier attempts 
to quantify global estimates of neonates aﬀ ected by sickle 
haemoglobin,7 several limitations remain. These 
limitations include the scarcity or accessibility of 
information about HbS allele frequency in some 
important areas; the presence of confounding factors 
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Figure 5: Comparison plots of predicted national SS neonate estimates with Modell and Darlison’s estimates 
for the SEARO and WPRO regions
Red dots show our estimates (termed MAP) with IQRs shown as red lines. Blue dots represent Modell and 
Darlison’s estimates.7 (A) SEARO. (B) WPRO. SEARO=Regional Oﬃ  ce for South-East Asia. WPRO=Regional Oﬃ  ce for 
the Western Paciﬁ c.
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such as non-random mating; and the interactions with 
other inherited blood disorders.
Contemporary HbS allele frequency heterogeneity over 
short distances and between ethnic groups can only partly 
be explained by the selection pressure of malaria, especially 
in India.4 Other factors, such as environmental variables 
(eg, altitude) or diﬀ erences in social behaviour (eg, 
consanguinity or endogamy)33 also contribute to HbS allele 
frequency. For various reasons, including ethical issues 
and the diﬃ  culty of deﬁ ning an ethnic group, such social 
factors are not consistently reported in HbS surveys. 
Therefore, cap turing spatial variations in these factors 
from a partial dataset is diﬃ  cult. As a consequence, the 
inclusion of ethnic origin or consanguinity would probably 
have added uncertainty to the model. Moreover, no 
consistent high-resolution global database of these factors 
is currently available. Deﬁ ning a minimum standard of 
information gathered and reported for new surveys (eg, 
sampling method, location, age group) would greatly 
facilitate such global studies.
Finally, our study focuses on AS and SS neonates. We are 
aware that these estimates only represent part of the 
burden caused by HbS. First, we have calculated neonate 
estimates, not all-age population estimates or disability-
adjusted life year losses from HbS.1 The feasibility of 
calculating such estimates is currently very limited because 
of a general paucity of information on the variations of 
clinical severity between haplotypes, and on mortality 
caused by HbS, both in low-income and high-income 
countries.34 Second, our estimates do not include indiv-
iduals with compound disorders such as haemoglobin 
SC disease or haemoglobin S-beta thalassaemia disease. 
Including these individuals would require a good 
knowledge of the distribution of haemoglobin C and 
β-thalassaemia, as well as of the interactions between these 
variants. Recent studies have shown that such interactions, 
or epistatic eﬀ ects, are complex.35,36 Unless similar rigorous 
quantitative methods are used to study related disorders 
and HbS mortality, reliable estimates of the general eco-
nomic and public health burden of haemoglobinopathies 
as a whole will be impossible to produce.
Having been neglected for decades, awareness of HbS 
and of its burden on public health services globally is 
ﬁ nally growing. Our study aimed to make optimal use of 
existing data to create a contemporary map of HbS allele 
frequency and calculate annual estimates of AS and SS 
neonates at various spatial scales. The global quantitative 
map presented here shows for the ﬁ rst time the 
contemporary distribution of HbS. Our estimates and 
associated precision measures provide a valuable result to 
guide public health decisions at various scales and to 
assess future changes.
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